Pink Sheet reporters and editors consider the upcoming COVID-19 vaccination campaign (:37), the virtue of advisory committees with only a few members (19:42), and the first FDA drug advertising untitled letter in a year (25:08).

Read More In The Pink Sheet

COVID Vaccines: XBB Strain Easy Call, But Disagreements Abound Between FDA, Advisors On Logistics

https://pink.pharmaintelligence.informa.com/PS148385/COVID-Vaccines-XBB-Strain-Easy-Call-But-Disagreements-Abound-Between-FDA-Advisors-On-Logistics

Are US FDA Advisory Committees Too Big? Lecanemab Shows Benefit Of Thinking Small

https://pink.pharmaintelligence.informa.com/PS148382/Are-US-FDA-Advisory-Committees-Too-Big-Lecanemab-Shows-Benefit-Of-Thinking-Small

With First Advertising Letter In 12 Months, US FDA Goes After Xeris’s Webpage Promotion Of Recorlev

https://pink.pharmaintelligence.informa.com/PS148371/With-First-Advertising-Letter-In-12-Months-US-FDA-Goes-After-Xeriss-Webpage-Promotion-Of-Recorlev